EG24459A - Soluble CTLA4 mutant molecules and uses thereof - Google Patents

Soluble CTLA4 mutant molecules and uses thereof

Info

Publication number
EG24459A
EG24459A EG20010548A EG20010548A EG24459A EG 24459 A EG24459 A EG 24459A EG 20010548 A EG20010548 A EG 20010548A EG 20010548 A EG20010548 A EG 20010548A EG 24459 A EG24459 A EG 24459A
Authority
EG
Egypt
Prior art keywords
soluble ctla4
mutant molecules
amino acid
ctla4
molecules
Prior art date
Application number
EG20010548A
Other languages
English (en)
Inventor
Robert J Peach
Joseph R Naemura
Peter S Linsley
Juergen Bajorath
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of EG24459A publication Critical patent/EG24459A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EG20010548A 2000-05-26 2001-05-23 Soluble CTLA4 mutant molecules and uses thereof EG24459A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57992700A 2000-05-26 2000-05-26
US21406500P 2000-06-26 2000-06-26

Publications (1)

Publication Number Publication Date
EG24459A true EG24459A (en) 2009-07-16

Family

ID=26908652

Family Applications (1)

Application Number Title Priority Date Filing Date
EG20010548A EG24459A (en) 2000-05-26 2001-05-23 Soluble CTLA4 mutant molecules and uses thereof

Country Status (41)

Country Link
EP (3) EP3029062A1 (oth)
JP (1) JP4328525B2 (oth)
KR (2) KR100889887B1 (oth)
CN (2) CN101255192A (oth)
AR (1) AR031699A1 (oth)
AT (1) ATE271066T1 (oth)
AU (2) AU6346601A (oth)
BE (1) BE2011C041I2 (oth)
BR (1) BRPI0111191B8 (oth)
CA (1) CA2409748C (oth)
CY (2) CY2011019I2 (oth)
CZ (1) CZ304451B6 (oth)
DE (2) DE60104282T2 (oth)
DK (1) DK1248802T3 (oth)
EC (1) ECSP024365A (oth)
EE (2) EE05557B1 (oth)
EG (1) EG24459A (oth)
ES (2) ES2225549T3 (oth)
FR (1) FR11C0053I2 (oth)
GE (1) GEP20053658B (oth)
HK (1) HK1048126B (oth)
HU (2) HU228137B1 (oth)
IL (1) IL152315A (oth)
LT (1) LT5133B (oth)
LU (1) LU91902I2 (oth)
LV (1) LV12994B (oth)
MX (1) MXPA02011534A (oth)
MY (1) MY136113A (oth)
NO (2) NO330797B1 (oth)
PE (1) PE20011338A1 (oth)
PL (1) PL206267B1 (oth)
PT (1) PT1248802E (oth)
RU (1) RU2283847C2 (oth)
SI (1) SI1248802T1 (oth)
SK (1) SK288131B6 (oth)
TR (1) TR200402703T4 (oth)
TW (2) TWI314933B (oth)
UA (1) UA87432C2 (oth)
UY (1) UY26723A1 (oth)
WO (1) WO2001092337A2 (oth)
ZA (1) ZA200208944B (oth)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887471B1 (en) 1991-06-27 2005-05-03 Bristol-Myers Squibb Company Method to inhibit T cell interactions with soluble B7
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
SI1372696T1 (sl) * 2000-07-03 2008-12-31 Bristol Myers Squibb Co Metoda za zdravljenje revmatskih bolezni z uporabo topne molekule ctla4
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
MXPA03010568A (es) 2001-05-23 2005-03-07 Squibb Bristol Myers Co Metodos para proteger trasplantes alogenicos de celulas de isletas usando moleculas mutantes ctla4 solubles.
WO2003088991A1 (en) * 2002-04-19 2003-10-30 Bristol-Myers Squibb Company Methods for treating an autoimmune disease using a soluble ctla4 molecule and a dmard or nsaid
DE10232697A1 (de) * 2002-07-15 2004-02-05 Universitätsklinikum Charité, Medizinische Fakultät der Humboldt-Universität zu Berlin Verwendung von CD152 zur Behandlung von Autoimmunkrankheiten und Entzündungen
CN101857851A (zh) * 2002-12-23 2010-10-13 布里斯托尔-迈尔斯斯奎布公司 用于蛋白质生产的哺乳动物细胞培养方法
DE60335024D1 (de) * 2002-12-23 2010-12-30 Bristol Myers Squibb Co Produktqualitätsverbesserung in säugerzellkulturverfahrenzur proteinproduktion
AU2003299971A1 (en) 2002-12-30 2004-07-29 Amgen Inc. Combination therapy with co-stimulatory factors
AU2004287431B2 (en) 2003-10-27 2010-03-11 Amgen Inc. Compositions and methods to modulate an immune response to an immunogenic therapeutic agent
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
EP2253644B1 (en) * 2005-12-20 2013-10-16 Bristol-Myers Squibb Company Compositions and methods for producing a composition
US7510844B2 (en) 2006-01-24 2009-03-31 Bristol-Myers Squibb Company CD86 and CD80 receptor competition assays
WO2008005290A2 (en) 2006-06-29 2008-01-10 The Trustees Of Columbia University In The City Of New York Methods for testing anti-thrombotic agents
GB0620934D0 (en) * 2006-10-20 2006-11-29 Cambridge Antibody Tech Protein variants
BRPI0720565A2 (pt) 2006-12-20 2013-09-17 Mmr Information Systems Inc anticorpos e mÉtodos para a sua preparaÇço e seu uso
AU2008319053B2 (en) 2007-11-01 2012-04-26 Astellas Pharma Inc. Immunosuppressive polypeptides and nucleic acids
NZ592420A (en) * 2008-10-02 2012-12-21 Emergent Product Dev Seattle Cd86 antagonist multi-target binding proteins
US9540426B2 (en) 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
CN106432474A (zh) 2010-03-12 2017-02-22 艾伯维生物医疗股份有限公司 Ctla4蛋白和其用途
KR20130129438A (ko) 2011-02-23 2013-11-28 암젠 인크 Uvc 노출을 위한 세포 배양 배지 및 이와 관련된 방법
WO2013010537A1 (en) 2011-07-20 2013-01-24 Aarhus Universitet Method of treating morphea
US9758566B2 (en) 2012-03-29 2017-09-12 The General Hospital Corporation Recombinant cytotoxic T-lymphocyte-associated protein 4 (CTLA4)
JP6228971B2 (ja) 2012-05-11 2017-11-08 メディミューン，エルエルシー Ｃｔｌａ−４バリアント
US8735359B2 (en) 2012-05-24 2014-05-27 Orban Biotech Llc Combinations of modalities for the treatment of diabetes
MX377570B (es) 2012-06-27 2025-03-10 Orban Biotech Llc Proteínas de fusión ctla4 para el tratamiento de la diabetes.
US20140112958A1 (en) 2012-10-24 2014-04-24 Mwm Biomodels Gmbh Pancreatic islets of transgenic LEA29Y animals for treating diabetes
CN104740608A (zh) * 2013-12-30 2015-07-01 上海中信国健药业股份有限公司 可溶性ctla4分子用于制备治疗类风湿性关节炎药物的用途
EP3094735A1 (en) 2014-01-13 2016-11-23 Amgen Inc. Regulating ornithine metabolism to manipulate the high mannose glycoform content of recombinant proteins
GB2523399B (en) 2014-02-25 2019-03-13 Orban Tihamer A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence
PT3152317T (pt) 2014-06-04 2019-04-18 Amgen Inc Métodos de colheita de culturas de células de mamíferos
ES2784503T3 (es) 2014-12-01 2020-09-28 Amgen Inc Procedimiento para manipular el nivel de contenido de glicano de una glicoproteína
US10590457B2 (en) 2015-02-11 2020-03-17 Bristol Myers-Squibb Company Compositions for cell culture and methods of using the same
EP3283508B1 (en) 2015-04-17 2021-03-17 Alpine Immune Sciences, Inc. Immunomodulatory proteins with tunable affinities
CA2997947A1 (en) 2015-09-09 2017-03-16 The Trustees Of Columbia University In The City Of New York Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease
CN108350416A (zh) 2015-11-09 2018-07-31 百时美施贵宝公司 操纵在cho细胞中产生的多肽的品质属性的方法
WO2018053506A1 (en) 2016-09-19 2018-03-22 Oncoimmune, Inc. Cd80 and cd86 binding protein compositions and uses thereof
CN107987153A (zh) * 2016-10-27 2018-05-04 广东香雪精准医疗技术有限公司 高亲和力的可溶性pd-1分子
WO2018195402A1 (en) 2017-04-20 2018-10-25 Egenesis, Inc. Methods for generating genetically modified animals
KR102813968B1 (ko) 2017-10-10 2025-05-29 알파인 이뮨 사이언시즈, 인코포레이티드 Ctla-4 변이체 면역조절 단백질 및 이의 용도
SG11202006148UA (en) 2018-01-03 2020-07-29 Alpine Immune Sciences Inc Multi-domain immunomodulatory proteins and methods of use thereof
CN109453383A (zh) * 2018-11-12 2019-03-12 陈慧慧 免疫检查点的抑制剂在制备治疗青光眼及其他眼部免疫损伤机制相关疾病药物中的应用
WO2020113141A2 (en) 2018-11-30 2020-06-04 Alpine Immune Sciences, Inc. Cd86 variant immunomodulatory proteins and uses thereof
WO2021038296A2 (en) 2019-08-27 2021-03-04 Tonix Pharma Holdings Limited Modified tff2 polypeptides
US11180540B2 (en) 2019-12-06 2021-11-23 Regeneron Pharmaceuticals, Inc. Anti-VEGF protein compositions and methods for producing the same
JP2023525034A (ja) 2020-05-08 2023-06-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｖｅｇｆトラップおよびミニトラップならびに眼障害およびがんの治療方法
US20220011318A1 (en) 2020-06-18 2022-01-13 Regeneron Pharmaceuticals, Inc. Heavy peptide approach to accurately measure unprocessed c-terminal lysine in antibodies
US20230287322A1 (en) 2020-07-28 2023-09-14 Seagen Inc. Methods and systems for producing polypeptides
WO2023115027A2 (en) 2021-12-16 2023-06-22 Bristol-Myers Squibb Company Detergent for viral inactivation
WO2023167847A2 (en) 2022-03-02 2023-09-07 Regeneron Pharmaceuticals, Inc. Bioreactor for antibody production

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US5851795A (en) * 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
DE69226871T3 (de) * 1991-06-27 2009-09-24 Bristol-Myers Squibb Co. CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung
ZA98533B (en) * 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
JP3521382B2 (ja) * 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
GB9809280D0 (en) * 1998-04-30 1998-07-01 Rpms Technology Ltd Immunosupression
WO2000019988A1 (en) * 1998-10-07 2000-04-13 Millennium Pharmaceuticals, Inc. NOVEL Th2-SPECIFIC MOLECULES AND USES THEREOF
SI1372696T1 (sl) * 2000-07-03 2008-12-31 Bristol Myers Squibb Co Metoda za zdravljenje revmatskih bolezni z uporabo topne molekule ctla4

Also Published As

Publication number Publication date
NO2011027I1 (no) 2012-01-09
MXPA02011534A (es) 2004-08-12
EP3029062A1 (en) 2016-06-08
NO2011027I2 (oth) 2011-12-15
FR11C0053I2 (fr) 2013-01-11
GEP20053658B (en) 2005-11-10
DE60104282T2 (de) 2005-10-13
FR11C0053I1 (oth) 2012-01-13
HK1048126A1 (en) 2003-03-21
DK1248802T3 (da) 2004-11-15
AU2001263466C1 (en) 2006-10-26
AR031699A1 (es) 2003-10-01
TR200402703T4 (tr) 2004-11-22
LV12994B (en) 2003-08-20
SK15702002A3 (sk) 2004-01-08
CY1117625T1 (el) 2017-04-26
AU6346601A (en) 2001-12-11
EP1536234A2 (en) 2005-06-01
RU2283847C2 (ru) 2006-09-20
HUS1300012I1 (hu) 2016-08-29
EE05557B1 (et) 2012-08-15
PL206267B1 (pl) 2010-07-30
ES2225549T3 (es) 2005-03-16
CA2409748A1 (en) 2001-12-06
HUP0302201A2 (hu) 2003-10-28
UY26723A1 (es) 2001-12-28
ECSP024365A (es) 2003-03-31
TWI319405B (en) 2010-01-11
CY2011019I1 (el) 2016-12-14
BR0111191A (pt) 2004-07-06
EP1536234B1 (en) 2016-03-16
KR100895134B1 (ko) 2009-05-04
PL366231A1 (en) 2005-01-24
EE200200659A (et) 2004-06-15
IL152315A0 (en) 2003-05-29
HK1048126B (en) 2005-03-04
EE201100050A (et) 2011-10-17
WO2001092337A2 (en) 2001-12-06
BRPI0111191B1 (pt) 2019-12-31
DE60104282D1 (de) 2004-08-19
JP4328525B2 (ja) 2009-09-09
HU228137B1 (en) 2012-12-28
HUP0302201A3 (en) 2010-01-28
ES2571852T3 (es) 2016-05-27
KR20030009502A (ko) 2003-01-29
LT5133B (lt) 2004-05-25
JP2004511213A (ja) 2004-04-15
TW200906857A (en) 2009-02-16
CZ304451B6 (cs) 2014-05-14
ZA200208944B (en) 2004-02-13
SK288131B6 (sk) 2013-10-02
NO20025656D0 (no) 2002-11-25
KR20070094019A (ko) 2007-09-19
LU91902I2 (fr) 2012-01-16
EP1248802B1 (en) 2004-07-14
KR100889887B1 (ko) 2009-03-24
IL152315A (en) 2010-04-15
EE05458B1 (et) 2011-08-15
BE2011C041I2 (oth) 2020-08-20
LT2002114A (en) 2003-12-29
BRPI0111191B8 (pt) 2021-05-25
EP1248802B9 (en) 2005-05-11
CY2011019I2 (el) 2016-12-14
EP1248802A2 (en) 2002-10-16
EP1536234A3 (en) 2009-06-03
CA2409748C (en) 2008-09-16
HK1071931A1 (en) 2005-08-05
CZ20023892A3 (cs) 2003-09-17
UA87432C2 (uk) 2009-07-27
NO330797B1 (no) 2011-07-18
PE20011338A1 (es) 2002-01-13
MY136113A (en) 2008-08-29
ATE271066T1 (de) 2004-07-15
PT1248802E (pt) 2004-11-30
AU2001263466B2 (en) 2006-04-27
SI1248802T1 (en) 2005-02-28
CN1309735C (zh) 2007-04-11
TWI314933B (en) 2009-09-21
CN1441810A (zh) 2003-09-10
WO2001092337A3 (en) 2002-05-10
CN101255192A (zh) 2008-09-03
DE122011100063I1 (de) 2012-06-14
NO20025656L (no) 2002-11-25

Similar Documents

Publication Publication Date Title
TWI319405B (en) Soluble ctla4 mutant molecules and uses thereof
MX339406B (es) Antigenos de neisseria meningitidis y composiciones que los contienen.
BR0010361A (pt) Seq ências genÈmicas de neisseria e uso destas
SG156547A1 (en) Human monoclonal antibodies to ctla-4
EP1559795A3 (en) Neisseria genomic sequences and methods of their use
MX2007012222A (es) Metodo para tratamiento de trastornos inmunes asociados con trasplante de injerto con moleculas mutantes ctla4 solubles.